Paul Hockings (Senior Director MR Imaging at Antaros Medical and Adjunct Professor at Chalmers University of Technology), and Nicolau Beckmann (Associate Director, Group Head Imaging & Histology at Novartis Institutes for BioMedical Research) have contributed a new chapter in the latest edition of Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. The chapter, called “Magnetic Resonance Imaging in Pharmaceutical Safety Assessment“, provides a brief overview of where Magnetic Resonance Imaging (MRI) assays can add the most value in pre-clinical and translational drug development and outlines four examples of quantitative imaging biomarkers that can be applied in safety pharmacology studies.
The 3rd edition is edited by Franz J. Hock, Michael R. Gralinski, and Michael K. Pugsley. You can access it here.
Chapter Title: Magnetic Resonance Imaging in Pharmaceutical Safety Assessment
Book Title: Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
Authors: Hockings, P, Beckmann N
Find the publication here.